$3.86 $0.03 (0.0%)

03:37 PM EDT on 06/14/19

Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 4 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Current Price $3.86 Mkt Cap $426.2M
Open $3.81 P/E Ratio 0.00
Prev. Close $3.86 Div. (Yield) $0.00 (0.0%)
Daily Range $3.81 - $3.93 Volume 171,756
52-Wk Range $3.58 - $12.41 Avg. Daily Vol.

Caps

How do you think NASDAQ:DVAX will perform against the market?

Add Stock to CAPS Watchlist

All Players

198 Outperform
15 Underperform
 

All-Star Players

28 Outperform
7 Underperform
 

Wall Street

7 Outperform
0 Underperform
 

Top NASDAQ:DVAX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Patastic (26.21)
Submitted August 09, 2017

Heplisav Approval almost a lock. SD-101 shows great promise in combination with Keytruda (100% ORR). New lung cancer inhalable TLR agonist in combo with anti PD-1 going into trials this quarter. Partnership with AstraZeneca on a cure for… More

zzlangerhans (99.82)
Submitted November 14, 2016

The zzporte portfolio ate a large helping of dirt today with the announcement of the CRL for Heplisav. The CRL wasn't an enormous surprise, given the tortuous history of Heplisav and the cancellation of the Ad Comm. I probably wouldn't have bought… More

NASDAQ:DVAX VS S&P 500 (SPY)

Fools bullish on NASDAQ:DVAX are also bullish on:

Fools bearish on NASDAQ:DVAX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about DVAX.

Recs

0
Member Avatar TMFGBudwell (47.41) Submitted: 12/18/2017 4:17:46 AM : Outperform Start Price: $19.40 NASDAQ:DVAX Score: -88.22

Undervalued from a long-term growth perspective.

Recs

1
Member Avatar Patastic (26.21) Submitted: 8/9/2017 4:52:28 PM : Outperform Start Price: $16.25 NASDAQ:DVAX Score: -93.38

Heplisav Approval almost a lock. SD-101 shows great promise in combination with Keytruda (100% ORR). New lung cancer inhalable TLR agonist in combo with anti PD-1 going into trials this quarter. Partnership with AstraZeneca on a cure for asthma...Holy cow. I'm in long on this one.

Recs

0
Member Avatar rocknrook (55.68) Submitted: 1/19/2017 12:20:50 PM : Outperform Start Price: $4.30 NASDAQ:DVAX Score: -38.30

I think management is finally getting their act together on approval process. Hep drug should approve soon & other potentials in the pipeline. Once Hep comes through, I expect a large pop in value.

Leaderboard

Find the members with the highest scoring picks in DVAX.

Score Leader

MarkBiotech

MarkBiotech (< 20) Score: +296.26

The Score Leader is the player with the highest score across all their picks in DVAX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
mavimadero 41.23 10/9/2006 Underperform 3W $72.90 -94.71% +128.15% +222.85 0 Comment
hawkider 31.00 12/8/2006 Underperform 3Y $95.20 -95.95% +118.05% +214.00 1 Comment
dozer963 23.61 3/18/2008 Underperform NS $23.00 -83.22% +130.00% +213.21 0 Comment
HondurasAlan 73.53 1/8/2007 Underperform 3W $61.40 -93.71% +117.80% +211.51 0 Comment
Turkmenbashi 30.55 1/8/2007 Underperform NS $59.70 -93.53% +117.96% +211.49 0 Comment
cthomas1017 99.29 12/7/2012 Underperform 5Y $26.05 -85.18% +103.37% +188.56 0 Comment
rqtect < 20 2/27/2013 Underperform 3W $21.00 -81.62% +93.39% +175.01 0 Comment
rknapton 86.14 8/7/2013 Underperform 5Y $13.50 -71.41% +71.33% +142.74 1 Comment
brogers146 69.15 10/28/2013 Underperform 5Y $12.30 -68.62% +64.80% +133.42 0 Comment
hicksjmu567 81.55 10/30/2013 Underperform 3Y $12.50 -69.12% +64.18% +133.30 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackRBCCapMkts 85.57 8/1/2017 Outperform NS $16.25 -76.25% +17.14% -93.38 0 Comment
TrackJimCramer 86.18 8/6/2015 Outperform 3W $27.74 -86.09% +39.13% -125.21 0 Comment
TrackJPMorgan 84.74 3/23/2015 Outperform NS $24.39 -84.17% +37.76% -121.93 0 Comment
TrackJimCramer 86.18 11/21/2014 Underperform 3W $14.29 +94.12% +0.81% -93.31 8/6/2015 @ $27.74 0 Comment
TrackJimCramer 86.18 9/14/2012 Outperform 3W $45.50 -68.59% +40.37% -108.96 11/21/2014 @ $14.29 0 Comment
TrackMLVCo < 20 1/4/2012 Outperform NS $32.70 +44.65% +8.44% +36.21 4/17/2012 @ $47.30 0 Comment
TrackZacks < 20 12/27/2010 Outperform 3M $30.40 +37.17% +9.96% +27.21 11/9/2012 @ $41.70 1 Comment
TrackJefferies 78.16 11/8/2010 Outperform NS $21.40 -81.96% +136.94% -218.90 0 Comment
TrackWedbush 88.21 5/13/2010 Outperform NS $20.40 -81.08% +147.48% -228.56 0 Comment
TrackSusquehanna 87.55 9/10/2009 Outperform NS $29.50 -86.92% +180.60% -267.51 0 Comment
TrackZacks < 20 2/20/2008 Outperform 3M $49.50 -55.56% -4.12% -51.44 3/19/2008 @ $22.00 1 Comment
TrackCreditSuiss 87.94 10/3/2007 Outperform NS $45.00 -91.42% +97.45% -188.87 0 Comment
trackmerriman 67.82 12/20/2006 Outperform NS $92.60 -73.00% -8.10% -64.90 3/18/2008 @ $25.00 0 Comment
TrackJMP 82.79 11/30/2006 Outperform NS $99.00 -46.67% +3.87% -50.53 2/26/2007 @ $52.80 0 Comment

Advertisement